Cargando…

Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo

PURPOSE: Desmoplastic small round cell tumors (DSRCTs) are highly malignant and very rare soft tissue sarcomas with a high unmet need for new therapeutic options. Therefore, we examined poly(ADP-ribose) polymerase 1 (PARP1) and Schlafen-11 (SLFN11) expression in DSRCT tumor tissue and the combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Erp, Anke E. M., van Houdt, Laurens, Hillebrandt-Roeffen, Melissa H. S., van Bree, Niek F. H. N., Flucke, Uta E., Mentzel, Thomas, Shipley, Janet, Desar, Ingrid M. E., Fleuren, Emmy D. G., Versleijen-Jonkers, Yvonne M. H., van der Graaf, Winette T. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256072/ https://www.ncbi.nlm.nih.gov/pubmed/32279088 http://dx.doi.org/10.1007/s00432-020-03211-z

Ejemplares similares

Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma
por: van Erp, Anke E. M., et al.
Publicado: (2022)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

PARP inhibition in UV-associated angiosarcoma preclinical models
por: Weidema, Marije E., et al.
Publicado: (2021)

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent
por: van Erp, Anke E.M., et al.
Publicado: (2017)

The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
por: Fleuren, Emmy D.G., et al.
Publicado: (2014)

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
por: Tomassen, T., et al.
Publicado: (2022)

Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas
por: Weidema, Marije E., et al.
Publicado: (2019)

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
por: Vlenterie, Myrella, et al.
Publicado: (2016)

Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases
por: Tomassen, Tess, et al.
Publicado: (2023)

Immunohistochemical selection of biomarkers for tumor-targeted image-guided surgery of myxofibrosarcoma
por: de Gooyer, Jan Marie, et al.
Publicado: (2020)

Establishment and characterization of the first patient-derived radiation-induced angiosarcoma xenograft model (RT-AS5)
por: Versleijen-Jonkers, Yvonne M. H., et al.
Publicado: (2023)

Systemic Treatment for Adults with Synovial Sarcoma
por: Desar, Ingrid M. E., et al.
Publicado: (2018)

Next generation sequencing in synovial sarcoma reveals novel gene mutations
por: Vlenterie, Myrella, et al.
Publicado: (2015)

Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups
por: van Ravensteijn, Stefan G., et al.
Publicado: (2022)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study
por: van der Horst, Chiel A. J., et al.
Publicado: (2022)

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
por: Valiakhmetova, Andge, et al.
Publicado: (2019)

VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells
por: Navarro-Carrasco, Elena, et al.
Publicado: (2021)

Intra-Abdominal Desmoplastic Small Round Cell Tumor (DSRCT) and the Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Review
por: Reijers, Sophie J. M., et al.
Publicado: (2023)

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
por: Cecchini, Michael, et al.
Publicado: (2023)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

The Prognostic Relevance of MRI Characteristics in Myxofibrosarcoma Patients Treated with Neoadjuvant Radiotherapy
por: van Ravensteijn, Stefan G., et al.
Publicado: (2023)

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
por: Hanna, Catherine, et al.
Publicado: (2020)

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
por: Zampieri, Luca X., et al.
Publicado: (2021)

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
por: Frezza, Anna Maria, et al.
Publicado: (2014)

Desmoplastic melanoma morphology on Thinprep: a report of two cases
por: Van Ells, Becky L, et al.
Publicado: (2007)

Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
por: Zuidema, Sander, et al.
Publicado: (2019)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
por: Fulton, Ben, et al.
Publicado: (2017)

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
por: Stanzione, Marcello, et al.
Publicado: (2022)

Adult Desmoplastic Medulloblastoma
por: Al Anazi, Abdulrahman H., et al.
Publicado: (2017)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
por: de Haan, R., et al.
Publicado: (2019)

The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes
por: Soomers, Vicky, et al.
Publicado: (2020)

Desmoid is not a sarcoma; reply to Sachdev et al.
por: van der Graaf, Winette T.A., et al.
Publicado: (2023)

A real or apparent decrease in glomerular filtration rate in patients using olaparib?
por: Bruin, M. A. C., et al.
Publicado: (2020)

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
por: Desar, Ingrid M E, et al.
Publicado: (2016)

Desmoplastic ameloblastoma
por: Majumdar, Sumit, et al.
Publicado: (2014)

Desmoplastic Melanoma
por: Kordahi, Anthony Maurice, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2ceuct2ksr4bu5sig9jlgmdv72